Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 4, 2010, Pages 389-393

  Hatano, Hiroyu ^a   Lampiris, Harry ^a,b   Fransen, Signe ^c   Gupta, Soumi ^c   Huang, Wei ^c   Hoh, Rebecca ^a   Martin, Jeffrey N ^a   Lalezari, Jacob ^d   Bangsberg, David ^e   Petropoulos, Christos ^c   Deeks, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d Quest Clinical Research   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

drug resistance; integrase inhibitors; virologic failure

Indexed keywords

ARGININE; ASPARAGINE; ELVITEGRAVIR; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HISTIDINE; INTEGRASE; LYSINE; RALTEGRAVIR; SERINE; TYROSINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; INTEGRASE INHIBITOR; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; BLOOD; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; GENETICS; MIDDLE AGED; PHYSIOLOGY; TIME; TREATMENT FAILURE;

ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 77955504896     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181c42ea4     Document Type: Article

References (13)

1. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-570.
2. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359: 1429-1441.
3. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
4. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-1178.
5. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287:646-650.
6. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007; 46:125-133.
7. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-1269.
8. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008; 359:355-365.
9. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008; 359:339-354.
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med. 2008;16:62-68.
11. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004;305:528-532.
12. Wirden M, Simon A, Schneider L, et al. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J Antimicrob Chemother. 2009;64:1087-1090.
13. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-231.